A small, prospective study found 50% of patients with severe hidradenitis suppurativa (HS) experienced improvements in their disease after receiving ustekinumab intravenous induction.
In the prospective, descriptive study, the researchers analyzed data of 6 patients with severe HS (Hurley stage III) who were treated with ustekinumab intravenous induction followed by subcutaneous maintenance treatment from January 1, 2017 through August 28, 2019 at a tertiary general university hospital in Spain (50% female). Patients were followed for 8 weeks.
You may also like...
Which HS Treatment Option Is Associated With Better Response?
Biologic May be Effective for Patients With HS
Recurrent Rates Higher With Partial Excision for HS
The researchers evaluated the effectiveness of ustekinumab using the International Hidradenitis Suppurativa Severity Score System (IHS4) and Hidradenitis Suppurativa Clinical Response (HiSCR), as well as incidence and severity of adverse events. In addition, they assessed patient demographics, comorbidities, and previous and concomitant therapy use.
Prior to initiating treatment with ustekinumab, patients had received adalimumab (100%), antibiotics (100%), surgery (66.67%), retinoids (66.6%), and immunomodulators (33.3%). During the study period, the researchers noted that 50% of patients received concomitant antibiotics, 16.6% underwent surgery, and 16.6% received retinoids.
Overall, 50% of patients achieved HiSCR without any treatment-related adverse effect after 4 weeks of treatment, the researchers concluded.
While the small study size and short period are limitations, the findings may be helpful for physicians treating patients with severe HS that is refractory to other therapeutic options.
Sánchez Martínez EM, Sáez Belló M, García Ruiz R, Moneva Léniz LM, Mateu Puchades A. Effectiveness and safety of ustekinumab in patients with hidradenitis suppurativa using intravenous induction. Abstract presented at: 2020 American Academy of Dermatology Virtual Meeting Experience; June 12-14, 2020.